olvimulogene nanivacirepvec
AXP000093.1 · Oncolytic virus
- Platform
- vaccinia virus (Lister/LIVP, triple-deleted)
- Originator
- Genelux
- Sponsor
- Genelux
Names
| Name | Type | Source |
|---|---|---|
| olvimulogene nanivacirepvec | preferred name, INN | curator, ncit |
| Olvi-Vec | brand | ncit |
| GLV-1h68 | code | ncit |
| GL-ONC1 | former code | ncit |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Lister (LIVP)
- Replication
- conditionally replicating
- Modifications
- F14.5L, J2R (thymidine kinase) and A56R (haemagglutinin) loci disrupted by expression cassettes
- Transgenes
- RUC-GFP, LacZ, gusA
- Route
- intravenous, intraperitoneal, intrapleural, intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C79833
- Wikidata
- Q140775697
- FDA UNII
- CF19SF72O5
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Recruiting | Phase 2 | 2024-09-26 | 2027-02 | 142 | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV |
| NCT07136285 | Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | Recruiting | Phase 1/2 | 2023-07-24 | 2026-12 | 27 | SCLC, Extensive Stage |
| NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Recruiting | Phase 3 | 2022-08-31 | 2026-12 | 186 | Endometrioid Ovarian Cancer; Fallopian Tube Cancer; High-grade Serous Ovarian Cancer; Ovarian Clear Cell Carcinoma; Platinum-refractory Ovarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Cancer |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | Completed | Phase 1/2 | 2016-05 | 2021-12-31 | 46 | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Carcinomatosis |
| NCT02714374 | GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers | Terminated | Phase 1 | 2016-03-25 | 2019-08-06 | 5 | Solid Organ Cancers |
| NCT01766739 | Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma | Completed | Phase 1 | 2013-01 | 2024-10-24 | 18 | Lung Cancer |
| NCT01584284 | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer | Completed | Phase 1 | 2012-04 | 2015-06 | 19 | Cancer of Head and Neck |
| NCT01443260 | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | Completed | Phase 1/2 | 2012-02 | 2014-09 | 9 | Peritoneal Carcinomatosis |
| NCT00794131 | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | Completed | Phase 1 | 2008-11 | 2015-11 | 43 | Advanced Cancers (Solid Tumors) |
| NCT03420430 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | No longer available | Acute Myeloid Leukemia (6 Patients); Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42383154 | Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer. | Gynecologic oncology reports | 2026 | cited by trial NCT02759588 |
| PMID 42780413 | Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report. | Frontiers in oncology | 2026 | name in title: Olvi-Vec |
| PMID 36875061 | Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. | Frontiers in immunology | 2023 | cited by trial NCT01766739 |
| PMID 37227734 | Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. | JAMA oncology | 2023 | cited by trial NCT02759588 |
| PMID 37666539 | A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2023 | cited by trial NCT05281471 |
| PMID 34686353 | A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. | Gynecologic oncology | 2021 | cited by trial NCT05281471 |
| PMID 31567308 | Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. | Anti-cancer drugs | 2019 | name in title: GL-ONC1 |
| PMID 29773661 | Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2018 | cited by trial NCT01443260 |
| PMID 28679776 | Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2017 | name in title: GL-ONC1 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42636898 | Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy. | Immunology letters | 2026 | name in abstract: olvimulogene nanivacirepvec |
| PMID 32631270 | Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms. | BMC cancer | 2020 | name in title: GLV-1h68 |
| PMID 30885937 | PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in abstract: GLV-1h68 |
| PMID 31142183 | Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. | Bioengineered | 2019 | name in abstract: GLV-1h68 |
| PMID 28607950 | Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine. | Molecular therapy oncolytics | 2017 | name in title: GLV-1h68 |
| PMID 25244076 | Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus. | Head & neck | 2016 | name in abstract: GLV-1h68 |
| PMID 27116656 | Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma. | International journal of cancer | 2016 | name in abstract: GLV-1h68 |
| PMID 27783991 | Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. | Oncotarget | 2016 | name in abstract: GLV-1h68 |
| PMID 24978211 | Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma. | International journal of cancer | 2015 | name in abstract: GLV-1h68 |
| PMID 26072410 | Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring. | Methods in molecular biology (Clifton, N.J.) | 2015 | name in title: GLV-1h68 |
| PMID 26348361 | Drug-Encoded Biomarkers for Monitoring Biological Therapies. | PloS one | 2015 | name in abstract: GLV-1h68 |
| PMID 26584530 | Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma. | Cancer gene therapy | 2015 | name in title: GLV-1h68 |
| PMID 23624923 | Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. | Oncogene | 2014 | name in abstract: GLV-1h68 |
| PMID 24957667 | Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. | Surgery | 2014 | name in title: GLV-1h68 |
| PMID 25030093 | Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. | Journal of translational medicine | 2014 | name in abstract: GLV-1h68 |
| PMID 25482233 | Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models. | Bioengineered | 2014 | name in abstract: GLV-1h68 |
| PMID 23429949 | Oncolytic vaccinia virus therapy of salivary gland carcinoma. | JAMA otolaryngology-- head & neck surgery | 2013 | name in abstract: GLV-1h68 |
| PMID 23441176 | Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI). | PloS one | 2013 | name in abstract: GLV-1h68 |
| PMID 23531320 | Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. | Journal of translational medicine | 2013 | name in title: GLV-1h68 |
| PMID 23729266 | Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. | International journal of cancer | 2013 | name in abstract: GLV-1h68 |
| PMID 23765443 | Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice. | Molecular therapy : the journal of the American Society of Gene Therapy | 2013 | name in abstract: GLV-1h68 |
| PMID 22341347 | Effective oncolytic vaccinia therapy for human sarcomas. | The Journal of surgical research | 2012 | name in abstract: GLV-1h68 |
| PMID 22379115 | Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2012 | name in abstract: GLV-1h68 |
| PMID 22615950 | Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. | PloS one | 2012 | name in abstract: GLV-1h68 |
| PMID 22901246 | Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. | Journal of translational medicine | 2012 | name in title: GLV-1h68 |
| PMID 22912675 | Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter. | PloS one | 2012 | name in abstract: GLV-1h68 |
| PMID 22917220 | Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. | BMC cancer | 2012 | name in abstract: GLV-1h68 |
| PMID 23049897 | Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice. | PloS one | 2012 | name in title: GLV-1h68 |
| PMID 23131031 | Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. | Human gene therapy methods | 2012 | name in abstract: GLV-1h68 |
| PMID 20829890 | Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA. | Cancer gene therapy | 2011 | name in title: GLV-1h68 |
| PMID 21249314 | Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts. | International journal of oncology | 2011 | name in abstract: GLV-1h68 |
| PMID 21453532 | Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. | Journal of translational medicine | 2011 | name in abstract: GLV-1h68 |
| PMID 21779374 | Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. | PloS one | 2011 | name in title: GLV-1h68 |
| PMID 21951588 | Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. | Journal of translational medicine | 2011 | name in abstract: GLV-1h68 |
| PMID 22011439 | Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. | BMC cancer | 2011 | name in title: GLV-1h68 |
| PMID 20379368 | Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. | Journal of biomedicine & biotechnology | 2010 | name in title: GLV-1h68 |
| PMID 20631910 | Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. | Journal of oncology | 2010 | name in title: GLV-1h68 |
| PMID 18949014 | Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. | Cancer gene therapy | 2009 | name in abstract: GLV-1h68 |
| PMID 19035444 | Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model. | International journal of cancer | 2009 | name in title: GLV-1h68 |
| PMID 19139123 | Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. | Molecular cancer therapeutics | 2009 | name in title: GLV-1h68 |
| PMID 19287510 | A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. | Molecular medicine (Cambridge, Mass.) | 2009 | name in abstract: GLV-1h68 |
| PMID 19580655 | Oncolytic vaccinia therapy of squamous cell carcinoma. | Molecular cancer | 2009 | name in abstract: GLV-1h68 |
| PMID 19583830 | Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. | BMC genomics | 2009 | name in title: GLV-1h68 |
| PMID 19617539 | Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. | Proceedings of the National Academy of Sciences of the United States of America | 2009 | name in abstract: GLV-1h68 |
| PMID 19701652 | The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. | Molecular genetics and genomics : MGG | 2009 | name in title: GLV-1h68 |
| PMID 18697871 | Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. | The Journal of clinical endocrinology and metabolism | 2008 | name in abstract: GLV-1h68 |
| PMID 18754710 | Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. | Human gene therapy | 2008 | name in title: GLV-1h68 |
| PMID 17942938 | Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. | Cancer research | 2007 | name in abstract: GLV-1h68 |
| PMID 18063085 | Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. | Surgery | 2007 | name in abstract: GLV-1h68 |
Notes
GLV-1h68/GL-ONC1, renamed Olvi-Vec and given the INN olvimulogene nanivacirepvec. Dosed intravenously, intraperitoneally and intrapleurally; phase 3 OnPrime (GOG-3076) in platinum-resistant ovarian cancer ongoing.
How to cite
olvimulogene nanivacirepvec (AXP000093.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000093.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.